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An almost uniformly neglected area of respiratory disease 
management is the non-pharmacological component. Most 
patients with chronic respiratory illnesses will lose their exercise 
capacity (deconditioning) as the illness progressively limits physical 
activity. It is usually not appreciated that as medication improves 
the disease state and static lung function, normalisation of physical 
activities does not automatically ensue – it has to be re-established. 
Many patients with obstructive lung disease will inappropriately 
use rescue bronchodilator therapy when experiencing dyspnoea 
with exertion, whereas the real problem is that of deconditioning. 
Practitioners often do not have time to define this problem carefully 
or advise patients adequately. A careful history and evaluation of 
patients will delineate the precise reason for dyspnoea and the 
appropriate management.  
For chronic obstructive pulmonary disease (COPD), in particular, 
non-pharmacological treatments include smoking cessation 
strategies, pulmonary rehabilitation, ventilatory support, 
endobronchial treatments and various forms of surgical treatments 
including bullectomy, lung volume reduction surgery and lung 
transplantation. Smoking cessation and domiciliary oxygen 
supplementation in advanced cases remain the only interventions 
with a proven mortality benefit in COPD.1
This review further elaborates on these non-pharmacological 
interventions, with particular emphasis on pulmonary 
rehabilitation.
Vicious cycle of COPD
The commonest symptom associated with COPD  is progressive 
dyspnoea, which leads to limitation of everyday physical activities. 
Inactivity promotes further physical deconditioning with associated 
loss of muscle mass. Advanced COPD is associated with systemic 
inflammation and increased circulating levels of cytokines, such as 
tumour necrosis factor-alpha (TNF-alpha), which further promote 
muscle loss and cachexia. Deconditioning aggravates dyspnoea 
with further limitation of activities and precipitation of a vicious 
cycle (Fig. 1). Limitation of activity also promotes social isolation 
of COPD patients, with an increased risk of depression and anxiety, 
which commonly remain undiagnosed and untreated.
Pulmonary rehabilitation
Pulmonary rehabilitation is a broad therapeutic concept. It is 
defined by international respiratory societies as an evidence-based, 
multidisciplinary and comprehensive intervention for patients 
with chronic respiratory diseases who are symptomatic and  often 
limited in their activities of daily life.2 
Pulmonary rehabilitation is usually provided in the form of a 
structured programme involving various health care professionals, 
including physicians, physiotherapists, biokineticists, dieticians 
and psychologists. A supervised exercise programme is the 
main component of a rehabilitation programme and is usually 
combined with patient education, nutritional assessment and 
psychological support. Pulmonary rehabilitation aims to break 
the aforementioned vicious cycle of COPD by improving exercise 
capability and conditioning. The proven benefits of pulmonary 
rehabilitation are summarised in Table I.
In terms of patient selection, rehabilitation is appropriate for COPD 
patients of all grades of severity, although some data suggest that 
severely incapacitated patients may  not benefit.3  Patients selected 
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Many patients with 
obstructive lung disease 
will inappropriately use 
rescue bronchodilator 
therapy when experiencing 
dyspnoea with exertion, 
whereas the real problem is 
that of deconditioning. 
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Fig. 1. This diagram illustrates how the various complications of 
COPD lead to vicious cycles that result in deconditioning.
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for pulmonary rehabilitation programmes 
should be highly motivated. Current smok-
ers are usually not considered for rehabilita-
tion unless they also partake in a smoking 
cessation programme, as there have been re-
ports that smokers are less likely to complete 
a rehabilitation programme.1,4
The minimum duration of an effective ex-
ercise programme in pulmonary rehabilita-
tion is currently not known, although guide-
lines suggest 6 weeks.1,2 Longer programmes, 
however, are associated with better results, 
albeit at increased costs. Exercise should be 
performed at least three times per week to 
achieve physiological benefits.2 Where re-
sources are limited, supervised training ses-
sions can be combined with unsupervised 
home sessions.
Exercise usually takes the form of lower-
extremity endurance training. This can be in 
the form of simple walking exercises or the 
use of a treadmill or a stationary cycle. The 
patients’ maximal exercise capability should 
be assessed by formal cardiopulmonary 
exercise testing before the start of the 
rehabilitation programme. During training 
the intensity should be maintained at a level 
of more than 60% of this capacity – ideally 
for more than 30 minutes. Interval training 
is an alternative in patients unable to achieve 
the desired intensity or duration of exercise 
and consists of shorter bursts of high-
intensity exercise combined with periods of 
lower-intensity exercise.2  Lower-extremity 
strength training can be combined with 
endurance training and achieves better 
results in terms of improvements in muscle 
mass compared with endurance training 
alone. Some programmes also include 
upper-extremity training with arm cycle 
ergometry, free weights or elastic bands, 
as many activities of daily living primarily 
involve the use of upper extremity muscles. 
It is important that bronchodilator therapy 
be optimised before exercise to enhance 
performance. Patients on long-term oxygen 
treatment should also continue this during 
exercise and may even require higher flow 
rates than at rest. 
Transcutaneous, neuromuscular electrical 
stimulation involves passive stimulation of 
contraction of peripheral muscles to elicit a 
training effect. It can be used as an adjunct 
to conventional forms of exercise and can 
also be used to improve peripheral muscle 
strength in severely incapacitated and even 
bed-bound patients. It has also been used in 
the setting of acute exacerbations of COPD, 
thereby allowing continued training.2,5
Other less conventional forms of training 
that have been used in rehabilitation 
programmes include breathing retraining 
and ventilatory muscle training. Patients 
with COPD may have a rapid, shallow 
breathing pattern that is deleterious to 
ventilation and gas exchange. Retraining 
with breathing techniques that employ yoga 
or pursed lip breathing has, in some studies, 
led to improvements in dyspnoea.6 Attempts 
at improving ventilatory muscle strength 
or endurance with these manoeuvres have 
yielded mixed results.7
Nutritional assessment should also form part 
of a pulmonary rehabilitation programme. 
Cachexia and loss of muscle mass are part 
of the systemic complications of COPD 
and independent predictors of mortality. 
Nutritional supplementation should be 
considered in individuals with a body mass 
index (BMI) below 21.1,2,5 
The use of anabolic steroids, growth hor-
mone, testosterone and creatine supplemen-
tation has also been investigated but has so 
far not proven to be beneficial.2
Patient education is integral to any 
rehabilitation programme and should include 
aspects of medication, nutrition and smoking 
cessation as well as guided self-management, 
i.e. early recognition of exacerbations.
Depression and anxiety are also highly 
prevalent in COPD patients and are related 
to deterioration in functional ability and 
resultant social isolation.1,2
Participating in a rehabilitation programme 
will commonly lead to an improvement 
of these symptoms purely by promoting 
social interaction of patients and improving 
functional ability. Psychological assessment as 
part of a rehabilitation programme can identify 
individuals who may benefit from further 




NPPV delivered by a nasal or facial mask 
aims to improve hypoventilation and provide 
respiratory muscle rest in patients with 
COPD. Although NPPV is highly useful in 
severe exacerbations of COPD, it has not 
been shown to be beneficial in stable COPD 
patients.5 An exception is the COPD patient 
with concomitant obstructive sleep apnoea 
or obesity-hypoventilation syndrome.
Surgery for COPD
Three types of surgical procedures are used 
in the management of COPD:
•    Bullectomy can be considered for selected 
patients with large emphysematous 
bullae not contributing to gas exchange. 
The procedure aims to decompress the 
underlying lung parenchyma, leading 
to improvements in dyspnoea and lung 
function, and can be performed as a 
thoracoscopic procedure. Bullectomy 
should only be considered when a bulla 
occupies more than 50% of the volume of a 
hemithorax with evidence of compression 
of underlying functioning lung tissue.5
•    Lung volume reduction surgery (LVRS) 
involves the removal of lung tissue in an 
attempt to improve hyperinflation. It also 
improves respiratory muscle function 
by resetting the position of the flattened 
diaphragms and improves radial traction 
on the airways with resultant decrease 
in expiratory airway collapse. This 
procedure was commonly performed in 
the 1990s, but was subsequently shown 
not to be of benefit in an unselected 
A supervised exercise programme is 
the main component of a rehabilitation 
programme and is usually combined 
with patient education, nutritional 
assessment and psychological support.
Smoking cessation and domiciliary 
oxygen supplementation in advanced 
cases remain the only interventions 
with a proven mortality benefit in COPD.
Table I. Benefits of pulmonary 
rehabilitation in COPD
•    Improvement in exercise tolerance
•    Reduction in dyspnoea
•    Improvement in health-related  
quality of life
•    Reduction in hospitalisation and 
health care expenditure
•    Reduction in anxiety, depression and 
social isolation
•    Possibly improved survival
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COPD population.8   However, in selected 
patients with severe effort intolerance and 
predominantly upper-lobe emphysema, 
LVRS can lead to improvements in 
functional status and mortality.
•    Although not widely performed in South 
Africa, lung transplantation is an option 
in advanced cases of COPD and is the 
commonest indication for single lung 
transplantation in most centres where this 
procedure is performed. In experienced 
centres, the 5-year survival after lung 
transplantation currently exceeds 60%. 
Bronchoscopic lung 
volume reduction (BLVR)
BLVR aims to provide the same benefits 
as LVRS by placing endobronchial devices 
via a bronchoscope into airways supplying 
emphysematous, hyperinflated parts of the 
lung. These devices function as one-way 
valves, allowing air to exit the targeted lobe 
and also allowing drainage of secretions.9 
Unfortunately, defects in the interlobar 
fissures of the lung can inhibit collapse 
of targeted areas by providing collateral 
ventilation. Early trials using endobronchial 
valve treatment have shown modest results 
in terms of improving lung function and 
exercise tolerance. It is likely that future trials 
will identify certain subgroups of COPD 
patients who might benefit from BLVR, as is 
the case with LVRS and improved devices.
Smoking cessation 
strategies
Smoking cessation is the only intervention 
that unequivocally slows the relentless 
decline in lung function in COPD patients. 
Although pharmacotherapy with nicotine 
replacement, buproprion (Zyban) and the 
recently introduced varenicline are very 
useful adjuncts, behavioural therapy forms 
the cornerstone of any smoking cessation 
programme. 
All health care professionals should give brief 
smoking cessation advice to every smoker 
with every patient contact. Brief advice can 
be summarised as 5 As:
•    ASK: Enquire about smoking habits with 
every contact.
•    ADVISE: Strongly advise all smokers to 
quit.
•    ASSESS: Determine willingness to make 
an attempt to quit.
•    ASSIST: Aid the patient in quitting by 
referring for further counselling and 
providing pharmacotherapy.
•    ARRANGE: Schedule follow-up contact.
The importance of the health professional in 
this regard cannot be adequately emphasised. 
Apart from removal of the primary respiratory 
aetiological agent there are a number of health 
benefits that accrue to other organ systems as 
well. 
In conclusion, COPD management needs 
to be holistic. Patients should be constantly 
encouraged to stop smoking and maintain 
cessation to limit progression of the disease 
and augment the benefits of pharmacotherapy. 
Improvement in functional status can only be 
achieved with a rehabilitation programme 
and overall health restitution with attention to 
all the components addressed in this review.
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In a nutshell 
•   COPD is associated with a vicious cycle of dyspnoea, deconditioning and social isolation.
•   Pulmonary rehabilitation aims to improve functional ability and social interaction.
•    Exercise training forms the most important part of pulmonary rehabilitation, but the latter also involves education and nutritional and 
psychological assessments.
•    Surgical procedures such as bullectomy, lung volume reduction surgery and lung transplantation are appropriate in selected COPD 
patients.
•    Bronchoscopic lung volume reduction is an experimental form of treatment aimed at decreasing hyperinflation by placement of 
endobronchial devices. 
•    Health care professionals must offer smoking cessation advice and therapeutic options to every smoker at every opportunity.
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